New research out of the United States points to a genetic anomaly in certain men with prostate cancer, which may impact their response to common drugs used to treat the disease.
Researchers found that abiraterone, a common prostate cancer drug, yields high levels of a testosterone-like byproduct in men with advanced disease who have a specific genetic variant.
Continue reading…